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Abstract
Background: The pathophysiology of chemotherapy-induced peripheral neuropathy (CIPN) is not well understood.
Currently, dose reduction is the only recommendation for alleviating symptoms, often leading to premature treatment
cessation. The primary aim of this analysis was to determine the association between components of diet during
taxane treatment for breast cancer and change in CIPN symptoms over treatment.
Methods: Women with stage II or III invasive breast cancer were enrolled into an ancillary study to the North American
Breast Cancer Intergroup phase III trial (S0221) led by the Southwest Oncology Group (SWOG). Questionnaires including a
food frequency questionnaire and the Functional Assessment of Cancer Treatment Gynecologic Oncology
Group—Neurotoxicity were administered to assess diet and neuropathic conditions at baseline and during
chemotherapy. Ordinal regression was used to estimate odds ratios (ORs) for associations between various
food groups and change in neuropathy score (< 10%, 10–30%, > 30%) (n = 900).
Results: The odds of worse neuropathy decreased by 21% for each increase in tertile of grain consumption
(OR = 0.79, 95% CI 0.66–0.94, p = 0.009). We also observed a nominal 19% increase with higher consumption
of citrus fruits (OR = 1.19, 95% CI 1.01–1.40, p = 0.05).
Conclusions: Distinguishing between those who experienced a moderate and a severe change in neuropathy, we
found that citrus fruit and grain consumption may play a role in the severity of symptoms. Since there are no existing
dietary recommendations for the management of CIPN, further research is needed to investigate whether there may
be certain foods that could worsen or alleviate neuropathy symptoms associated with treatment for breast cancer.
Trial registration: ClinicalTrials.gov, NCT03413761. Registered retrospectively on 29 January 2018.
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Background
Although effective for cancer treatment, use of chemother-
apy drugs often results in intolerable side effects that may
deter patients from completing planned treatments. One of
the most common reasons for prematurely discontinuing
treatment with drugs such as taxanes, epothilones, and
vinca alkaloids is the development of chemotherapy-in-
duced peripheral neuropathy (CIPN) [1, 2]. The most com-
mon CIPN symptoms include burning, tingling, numbness,
loss of proprioceptive sense, increased sensitivity to pain,
and reduced reflexes in the hands and feet. Aside from dis-
comfort, CIPN symptoms can cause loss of functional abil-
ity, affecting a patient’s ability to perform daily activities
and increasing the prevalence of falls [2, 3].
While the exact prevalence of CIPN is not known, a
recent meta-analysis estimated that approximately 50%
of breast cancer patients develop CIPN during taxane
treatment, with up to 80% of those still experiencing
symptoms at 6 months post treatment [4, 5]. While
some women experience improvement, over 40% have
reported symptoms at 3 years or more following treat-
ment [6–8]. The specific pathophysiology of CIPN is not
well understood, leaving patients with little to no options
to prevent these potentially debilitating side effects [9].
As a result, dose reduction can be recommended for al-
leviating acute symptoms and frequently leads to a pre-
mature cessation of treatment for those with severe
neuropathy [4].
Despite the importance of this clinical issue, the
American Society for Clinical Oncology treatment and
prevention practice guidelines concluded that insuffi-
cient evidence exists to support use of many nonphar-
maceutical interventions and that additional research is
warranted [5]. Some emerging literature suggests that
lifestyle factors including body mass index (BMI), phys-
ical activity, diet, and dietary supplement use may play a
role in the development and severity of CIPN [10]. Re-
cently, we reported that multivitamin use prior to and
during treatment was associated with reduced symptoms
of CIPN among breast cancer patients in the Diet, Exer-
cise, Lifestyle, and Cancer Prognosis (DELCaP) study
[11]. Many individuals, especially breast cancer patients,
may use dietary supplements to increase vitamin and
mineral consumption as a complement to traditional
cancer therapies [12, 13].
Dietary modifications have been explored in an effort
to self-manage neuropathy symptoms. A vegetarian diet
specifically has been found to improve symptoms among
those with diabetic neuropathy. It is unclear whether this
is due to the increased consumption of plant-based
foods containing a higher density of vitamins or avoid-
ance of certain foods [14, 15]. The association between
modifiable factors and CIPN is an understudied area. To
better understand the relationship between diet and
CIPN, we examined food groups consumed during
chemotherapy treatment and development of neur-
opathy symptoms to determine whether an association
exists between diet and neuropathy severity.
Methods
Participants
Data were obtained from the DELCaP study, an ancillary
study to a phase III therapeutic trial (S0221) led by the
South West Oncology Group (SWOG) (ClinicalTrials.gov
NCT00070564). DELCaP was developed to assess diet and
lifestyle data at multiple time points including baseline,
during, and post treatment. Detailed recruitment proce-
dures, randomization procedures, and inclusion criteria
for participation in both S0221 and DELCaP have been
described previously [11, 16]. Briefly, women enrolled in
S0221 had a confirmed diagnosis of stage II or III invasive
breast cancer and were randomized to one of four treat-
ment arms. Each patient received either doxorubicin plus
cyclophosphamide every 2 weeks with pegfilgrastim or
weekly doxorubicin plus daily cyclophosphamide with fil-
grastim. Patients then either received 12 weekly cycles of
paclitaxel or paclitaxel every 2 weeks with pegfilgrastim
for six cycles. Upon enrollment into S0221, participants
were contacted for participation in the DELCaP study.
Specifically, informed consent was obtained during the
consent for S0221, allowing research staff to contact po-
tential participants for inclusion in the DELCaP study.
This study was approved by the Institutional Review
Board at Roswell Park Cancer Institute and all participat-
ing institutions that enrolled patients.
A total of 1468 participants participated in the DEL-
CaP study; 1460 participants completed the baseline
questionnaire including foods usually eaten over the last
12 months prior to cancer diagnosis, and 1234 patients
completed the 6-month follow-up regarding diet during
treatment. In order to allow for the consideration of re-
peated measures, 226 participants who did not provide
information on at least 50% of foods in both the baseline
and follow-up questionnaires or had a difference > 10 in
the number of foods missing between baseline and
follow-up were excluded from this analysis. An add-
itional 340 participants who did not complete or had
missing values for the baseline or follow-up Functional
Assessment of Cancer Treatment Gynecologic Oncology
Group—Neurotoxicity (FACT/GOG-Ntx) questionnaire
were not included. The total study sample included 900
women in this analysis.
Data collection
DELCaP questionnaires were administered at four time
points throughout the study: at baseline, following com-
pletion of treatment, and annually for the following 2
years. A baseline questionnaire (Q1), administered at
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study enrollment but before treatment, included ques-
tions on race and ethnicity, menopausal status, height
and weight, smoking history, alcohol consumption, a
110-item food frequency questionnaire (FFQ) including
detailed questions regarding vitamin and dietary supple-
ment use, and the FACT/GOG-Ntx scale to assess
neuropathic conditions. The FFQ was adapted from the
validated Vitamins and Lifestyle (VitaL) study [17]. A
second questionnaire (Q2) was mailed to participants 6
months after registration to the trial, when chemother-
apy should have been completed. For the purpose of the
current analyses, we compared baseline to Q2 neur-
opathy symptoms to determine the change in neur-
opathy symptoms resulting from chemotherapy
treatments and FFQ data from Q2 to determine diet
during treatment (6-month recall).
For quality control purposes, data entry was performed
twice by different research staff and compared for accur-
acy and resolution of discrepancies.
Exposure assessment
In the baseline questionnaire, participants were asked to
indicate how often each food and beverage was usually
consumed over the last 12 months prior to diagnosis.
Food consumption frequency included never, 1 per
month, 2–3 per month, 1 per week, 2 per week, 3–4 per
week, 5–6 per week, 1 per day, and 2+ per day, with
additional options for a small, medium, and large serving
size for all foods. Beverage consumption frequency in-
cluded never, < 1 per month, 1–3 per month, 1 per
week, 2–4 per week, 5–6 per week, 1 per day, 2–3 per
day, 4–5 per day, and 6+ per day with small, medium,
and large serving size options. Standard medium serving
sizes were provided for reference for both food and bev-
erages. Missing food frequency values among those not
missing > 50% of foods were treated as a value of 0 (not
eaten). Missing serving sizes were assigned a default
medium value. An aggregate monthly total for each food
was computed by converting small, medium, and large
serving sizes into values of 0.5, 1, and 1.5, respectively,
which was then multiplied by the total monthly fre-
quency. The monthly sums of specific foods were totaled
to create food groups based on the University of Minne-
sota Nutrition Data System for Research and MyPlate
food groups (Table 1) [18, 19]. Food groups included cit-
rus fruits, other fruits, dark green vegetables, red/orange
vegetables, starchy vegetables, cruciferous vegetables,
beans/bean dishes, other vegetables, fish, poultry, red
meat, processed meat, other protein, dairy, grains,
sweets, fried foods, added fats, and alcohol. The
follow-up questionnaire included the same FFQ and
asked participants to indicate their diet over the previous
6 months (presumably reflecting diet during treatment)
during the time period in which neuropathy symptoms
would have developed or worsened. Data from this FFQ
were used in analysis and modeled as ordinal variables.
Outcome assessment
At baseline and in the follow-up questionnaire, partici-
pants completed an 11-item FACT/GOG-Ntx scale to
assess the severity of neuropathy symptoms during the
previous 7 days. Symptoms including numbness in
hands and feet, discomfort in hands and feet, joint and
muscle pain, hearing and ear trouble, trouble feeling,
and trouble walking were assessed on a 5-point scale
ranging from 4 = “Not at all”, 3 = “A little bit”, 2
= “Somewhat”, 1 = “Quite a bit”, to 0 = “Very much”.
Total baseline and 6-month follow-up scores were com-
puted and used to determine the percentage decrease in
neuropathy score, indicating a worsening of symptoms.
Previous literature has determined that a 10% or greater
decrease in FACT/GOG-Ntx score is clinically meaning-
ful for assessment of neuropathy [10, 20, 21]. Scores
were grouped into approximate tertiles based on
whether the participant experienced no to minimal in-
crease (< 10%), moderate increase (10–30%), or severe
increase (> 30%) in severity of neuropathy symptoms
and were modeled as an ordinal variable.
Statistical analysis
Demographic characteristics obtained from baseline
questionnaires included age, race, height, weight, meno-
pausal status, smoking status, highest education ob-
tained, and marital status. Height and weight at baseline
and follow-up were used to determine the BMI and
whether the participant had changed weight during
treatment. A chi-square test for independence and
one-way analysis of variance were performed to test for
differences in neuropathy score frequencies across
groups. Food groups were categorized as tertiles of
monthly servings during chemotherapy treatment and
compared using Pearson’s chi-square. Food frequencies
at baseline and follow-up were not independent and
were predictive of the other time point (0.36 ≤ r ≤ 0.58),
which is commonly observed in other studies of
long-term reproducibility and considered to fall within
an acceptable range for FFQs [22, 23]. Therefore, base-
line FFQ data were not included in the analysis.
Ordinal regression was used to estimate odds ratios
(ORs) and 95% confidence intervals (95% CIs) for the as-
sociations between each food group and change in neur-
opathy score. This modeling approach takes into
account the natural order of the multiple category out-
come, change in reported neuropathy score, or increas-
ing severity. The ordinal model also assumed that the
odds ratio of each outcome category was independent of
other categories (proportional odds assumption) [24].
The proportional odds assumption was first tested for
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Table 1 Classification of foods and food groups reported by patients enrolled in S0221a
Variable FFQ items included Individual foods included
All fruits Citrus fruits, other fruits (See listing below)
Citrus fruits Oranges, orange juice Oranges, grapefruit, and tangerines; 100% orange juice and
grapefruit juice
Other fruits Apples, bananas, peaches, apricots, dried fruit,
berries, melons, other fruits, 100% fruit juice
Apples, apple sauce, and pears; bananas; peaches, nectarines,
and plums; apricots (fresh or canned); dried fruit (other than
apricots) such as raisins or prunes; berries such as strawberries
and blueberries; cantaloupe, other melons, and mango; any
other fruit such as fruit cocktail, pineapples, and cherries;
other 100% fruit juice
All vegetables Dark green, red/orange, starchy, cruciferous,
beans/bean dishes, other vegetables
(See listing below)
Dark green Salad, greens Green salad (lettuce or spinach); cooked greens such as spinach,
mustard greens, or collards
Red/orange Salsa, tomatoes, carrots, winter squash,
tomato juice
Salsa (as in dip or foods); fresh tomatoes; carrots; winter squash
such as acorn or butternut, sweet potatoes and yams; tomato
juice, V-8, and other vegetable juice
Starchy Peas, boiled potatoes, corn Green peas; potatoes (boiled, baked, or mashed); corn
Cruciferous Broccoli, cauliflower Broccoli; cauliflower, cabbage, and Brussels sprouts
Beans/bean dishes Beans, bean soups Beans such as baked, refried, and chili without meat; bean
soups such as pea, lentil, and black bean
Other vegetables Peppers, green beans, summer squash, onions,
garlic, avocado
Green and red peppers and chilies; green or string beans;
summer squash, zucchini, and okra; onions and leeks; fresh
garlic including in cooking; avocado and guacamole
Protein sources
Fish Tuna, shell fish, white fish, dark fish Canned tuna, tuna salad, tuna casserole; shellfish, not fried
(shrimp, lobster, crab, and oysters; white fish (broiled or
baked) such as sole, halibut, and cod; dark fish (broiled or
baked) such as tuna or salmon
Poultry Chicken liver, roasted chicken Liver, chicken liver, and organ meats; chicken and turkey
(roasted, stewed, or broiled)
Red meat Beef, ground meat Beef, pork, ham, and lamb; ground meat including
hamburgers and meatloaf
Processed meat Bacon, low or reduced fat hot dog, regular hot
dog, lunch meats, other lunch meats
Bacon and breakfast sausage; low or reduced fat hot dogs
and sausage; lunch meats such as ham, turkey, and low fat
bologna; all other lunch meat such as bologna, salami, and
Spam
Other protein Peanut butter, tofu, eggs Peanut butter, peanuts, and other nuts and seeds; tofu,
tempeh, and products such as tofu hot dogs, soy burgers,
and tofu cheese; eggs
Other foods
Dairy Cottage and ricotta cheese, low or reduced fat
cheese, all other cheese, yogurt, milk, soymilk,
rice milk, milk added to cereal
Cottage cheese and ricotta cheese; low or reduced fat
cheese, including cheese used in cooking; all other cheeses,
such as American, cheddar, or cream cheese, including cheese
used in cooking; yogurt, all types, except for frozen; milk as a
beverage; soy milk; rice milk
Grains Cold cereal, cooked cereal, pancakes, muffins, white
bread, granola bar, sports or meal replacement bar,
low or nonfat chips, regular chips, low or nonfat
crackers, regular crackers, grains
Cold cereal; cooked cereals and grits; pancakes, French toast,
and waffles; muffins, scones, croissants, and biscuits; white
breads including bagels, rolls, and English muffins; granola
bars and cereal bars such as NutriGrain Bars; sports or meal
replacement bars such as Power Bars and Cliff Bars; low or
nonfat potato and tortilla chips, pretzels, and plain or low
fat microwave popcorn; regular potato and tortilla chips,
puffs, and microwave or buttered popcorn; low or nonfat
crackers such as saltines and SnackWell’s; regular crackers
such as Ritz and Wheat Thins; rice noodles and other grains
(as side dish)
Mongiovi et al. Breast Cancer Research          (2018) 20:146 Page 4 of 12
associations between the outcome and each food group
as well as the final model. Study arm, age in years,
self-identified race or ethnicity (non-Hispanic White,
Spanish/Latino/Hispanic, Black/African American,
other), BMI calculated from self-reported height and
weight, change in weight from diagnosis to post treat-
ment (lost weight, maintained weight, gained weight),
menopausal status (pre, post), smoking status (never,
former, current), highest level of education, and marital
status were assessed as potential covariates. Details re-
garding randomization of participants and the dose and
schedule of treatment have been described previously
[16]. Variables that were significantly associated with
both neuropathy category and at least two food groups
at p ≤ 0.20 were included in the final adjusted model
(age, race, BMI at baseline, and smoking status). The
final adjusted model included a single OR for CIPN se-
verity associated with each food group meeting the pro-
portional odds assumption and was interpreted as the
odds of reporting worse neuropathy at follow-up for in-
creased consumption of each food group (in tertiles)
[24]. Statistical tests performed were two-sided at α =
0.05. All analyses were performed using SAS 9.4 (SAS
Institute, Cary, NC, USA).
Results
As presented in Table 2, the mean age at baseline was
52.0 (SD = 9.7) years and the majority of women identi-
fied as non-Hispanic White (84.7%). As suggested by the
relatively young mean age, only 54.8% of women were
postmenopausal. Most were overweight or obese prior
to treatment (67.9%), with slightly fewer obese partici-
pants at follow-up (33.1% vs 35.6%); only 6.2% experi-
enced a greater than 10% decrease in body weight. The
majority of women reported never having smoked
(57.0%), at least some college or technical school
(73.4%), and being married or living as married (76.2%).
Women who experienced worse neuropathy were statis-
tically significantly older (p = 0.003), overweight or obese
(p = 0.03), experienced a change in weight from baseline
(p = 0.007), and were postmenopausal (p = 0.009). Most
women experienced either a moderate (34.0%) or severe
(34.8%) increase in neuropathy symptoms at the comple-
tion of treatment.
No significant differences in fruit and vegetable con-
sumption were observed across categories of neuropathy
(Table 3). Women with higher grain consumption had
less change in neuropathy (39.2%) whereas those who
had the lowest grain consumption had a greater increase
in neuropathy score (40.3%, p = 0.01) (Table 4). Those
who reported the greatest increase in neuropathy symp-
toms were more likely to abstain from alcohol than
those who reported little to no change (63.3% vs 55.6%
vs 58.0%, p = 0.009). A greater proportion of those who
reported consuming up to two servings of alcohol per
month experienced a moderate change in neuropathy
scores (27.5%) than those who reported a severe change
(15.7%) or no change (20.6%). Those who reported con-
suming over two servings of alcohol were least likely to
experience a moderate change (17.0%).
The proportional odds assumption held for associa-
tions between CIPN severity and all food groups ex-
cept for sweets, which was then treated as a nominal
categorical variable. The referent category for each
food group was the lowest tertile of intake. We ob-
served a significant unadjusted association between
grains and change in neuropathy (p = 0.002) suggest-
ing that higher grain consumption was associated
with less of an increase in neuropathy symptoms (OR
= 0.76, 95% CI 0.63–0.90) (data not shown). Both
Table 1 Classification of foods and food groups reported by patients enrolled in S0221a (Continued)
Variable FFQ items included Individual foods included
Sweets Jam, donuts, ice cream, frozen yogurt, pudding,
cookies and cakes, chocolate and candy, cranberry
juice, fruit drinks, soft drinks
Jam, jelly, honey, and syrup; ice cream and milk shakes; low
or nonfat frozen desserts such as low fat ice cream, frozen
yogurt, and sherbet; pudding, custard, and flan; donuts, pies,
and pastries; cookies and cakes; chocolate, candy bars, and
toffee; cranberry juice and other fruit juice cocktails; fruit
drinks fortified with vitamin C, such as Hi-C; regular soft
drinks
Fried foods Fried potatoes, fried fish, fried chicken French fries, fried potatoes, and hash browns; fried fish,
fish sandwich and fried shellfish (shrimp, oysters); fried
chicken including chicken nuggets and tenders
Added fats Butter on bread, butter added to dishes, mayonnaise,
salad dressing, gravy
Butter or margarine on breads, hot cereals, pancakes, etc.;
butter, margarine, sour cream, and other fat added to
vegetables, potatoes, and rice; mayonnaise and mayonnaise-
type spreads; salad dressing (all types); meat gravies
Alcohol Beer, red wine, white wine, liquor Beer (all types); red wine; white or rose wine; liquor and
mixed drinks
FFQ food frequency questionnaire
aBased on the University of Minnesota Nutrition Data System for Research and MyPlate food group classification [18, 19]
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Table 2 Change in self-reported neurotoxicity scores (FACT/GOG-Ntx subscale) pre to post chemotherapy treatment by population
characteristics (n = 900)
Total < 10%a 10–30%a > 30%a p valueb
Characteristic (mean ± SD) 281 (31.2) 306 (34.0) 313 (34.8)
Age at baseline (years) (52.0 ± 9.7)c 0.003
< 40 93 (10.3) 33 (11.7) 43 (14.1) 17 (5.4)
40–49 275 (30.6) 97 (34.5) 87 (28.5) 91 (29.1)
50–59 323 (35.9) 92 (32.7) 109 (35.7) 122 (39.0)
≥ 60 208 (23.1) 59 (21.0) 66 (21.6) 83 (26.5)
Race/ethnicity 0.98
Non-Hispanic White 762 (84.7) 238 (84.7) 259 (84.6) 265 (84.7)
Spanish/Latino/Hispanic 27 (3.0) 7 (2.5) 9 (2.9) 11 (3.5)
Black/African American 56 (6.2) 19 (6.8) 20 (6.5) 17 (5.4)
Other 55 (6.1) 17 (6.1) 18 (5.9) 20 (6.4)
BMI at baseline (kg/m2)c (28.7 ± 6.5) 0.03
Underweight (< 18.5) 8 (0.9) 6 (2.2) 1 (0.3) 1 (0.3)
Normal/underweight (18.5–24.9) 278 (31.3) 103 (37.1) 103 (34.1) 72 (23.3)
Overweight (25.0–29.9) 287 (32.3) 84 (30.22) 85 (28.2) 118 (38.2)
Obese (30.0+) 316 (35.6) 85 (30.6) 113 (37.4) 118 (38.2)
BMI at follow-up (kg/m2)c (28.5 ± 6.4) 0.16
Underweight (< 18.5) 8 (0.9) 4 (1.4) 2 (0.7) 2 (0.7)
Normal (18.5–24.9) 281 (31.7) 103 (37.2) 99 (33.0) 79 (25.6)
Overweight (25.0–29.9) 304 (34.3) 93 (33.6) 88 (29.3) 123 (39.8)
Obese (30.0+) 293 (33.1) 77 (27.8) 111 (37.0) 105 (34.0)
Change in weight during treatment 0.007
Lost weight 56 (6.2) 8 (2.9) 15 (4.9) 33 (10.5)
Did not change 772 (85.8) 256 (91.1) 263 (86.0) 253 (80.8)
Gained weight 72 (8.0) 17 (6.1) 28 (9.2) 27 (8.6)
Menopausal status 0.009
Pre 407 (45.2) 135 (48.0) 152 (49.7) 120 (38.3)
Post 493 (54.8) 146 (52.0) 154 (50.3) 193 (61.7)
Smoking status 0.09
Never 511 (57.0) 169 (60.4) 182 (59.7) 160 (51.3)
Former 285 (31.8) 84 (30.0) 94 (30.8) 107 (34.3)
Current 101 (11.3) 27 (9.6) 29 (9.5) 45 (14.4)
Highest education 0.21
Did not complete high school 51 (5.7) 22 (7.9) 11 (3.6) 18 (5.8)
High school 188 (21.0) 54 (19.4) 63 (20.7) 71 (22.7)
Some college or technical school 325 (36.3) 97 (34.8) 105 (34.5) 123 (39.3)
College graduate 196 (21.9) 64 (22.9) 70 (23.0) 62 (19.8)
Advanced degree 136 (15.2) 42 (15.1) 55 (18.1) 39 (12.5)
Marital status 0.80
Married/living as married 682 (76.2) 216 (77.1) 232 (76.6) 234 (75.0)
Widowed 38 (4.3) 15 (5.4) 9 (3.0) 14 (4.5)
Divorced/separated 127 (14.2) 35 (12.5) 45 (14.9) 47 (15.1)
Single/never married 48 (5.4) 14 (5.0) 17 (5.6) 17 (5.5)
Data presented as N (%)
SD standard deviation, FACT/GOG-Ntx Functional Assessment of Cancer Treatment Gynecologic Oncology Group—Neurotoxicity
aPercent increase in neuropathy severity (based on self-reported score)
bChi-square test for independence, analysis of variance for continuous variables (α = 0.05)
cModeled as continuous variable
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Table 3 Self-reported change in neurotoxicity scores by tertiles of monthly servingsa of fruit and vegetable during treatment (FACT/
GOG-Ntx subscale) (n = 900)
Food group Total < 10%a 10–30%b > 30%b p value c
All fruits 0.81
≤ 30.8 300 (33.3) 96 (34.2) 100 (32.7) 104 (33.2)
30.9–69.5 303 (33.7) 88 (31.3) 103 (33.7) 112 (35.8)
> 69.5 297 (33.0) 97 (34.5) 103 (33.7) 97 (31.0)
Citrus fruits 0.38
≤ 2.5 308 (34.2) 100 (35.6) 109 (35.6) 99 (31.6)
2.6–14.5 311 (34.6) 101 (35.9) 94 (30.7) 116 (37.1)
> 14.5 281 (31.2) 80 (28.5) 103 (33.7) 98 (31.3)
Other fruits 0.74
≤ 22.8 300 (33.3) 91 (32.4) 97 (31.7) 112 (35.8)
22.9–53.0 300 (33.3) 94 (33.5) 109 (35.6) 97 (31.0)
> 53.0 300 (33.3) 96 (34.2) 100 (32.7) 104 (33.2)
All vegetables 0.57
≤ 39.8 302 (33.6) 93 (33.1) 99 (32.4) 110 (35.1)
39.9–76.0 300 (33.3) 103 (36.7) 100 (32.7) 97 (31.0)
> 76.0 298 (33.1) 85 (30.3) 107 (35.0) 106 (33.9)
Dark green 0.14
≤3.8 276 (30.7) 85 (30.3) 88 (28.8) 103 (32.9)
3.9–12.0 333 (37.0) 103 (36.7) 105 (34.3) 125 (39.9)
> 12.0 291 (32.33) 93 (33.1) 113 (36.9) 85 (27.2)
Red/orange 0.49
≤ 8.0 316 (35.1) 97 (34.5) 99 (32.4) 120 (38.3)
8.1–20.5 291 (32.3) 97 (34.5) 100 (32.7) 94 (30.0)
> 20.5 293 (32.6) 87 (31.0) 107 (35.0) 99 (31.6)
Starchy 0.36
≤ 5.3 306 (34.0) 88 (31.3) 100 (32.7) 118 (37.7)
5.4–11.0 299 (33.2) 102 (36.3) 105 (34.3) 92 (29.4)
> 11.0 295 (32.8) 91 (32.4) 101 (33.0) 103 (32.9)
Cruciferous 0.79
≤ 2.5 334 (37.1) 97 (34.5) 119 (38.9) 118 (37.7)
2.6–6.5 275 (30.6) 93 (33.1) 89 (29.1) 93 (29.7)
> 6.5 291 (32.3) 91 (32.4) 98 (32.0) 102 (32.6)
Beans/bean dishes 0.74
≤ 0.5 336 (37.3) 105 (37.4) 106 (34.6) 125 (39.9)
0.6–2.5 284 (31.6) 89 (31.7) 99 (32.4) 96 (30.7)
> 2.5 280 (31.1) 87 (31.0) 101 (33.0) 92 (29.4)
Other vegetables 0.34
≤ 8.0 301 (33.4) 98 (34.9) 93 (30.4) 110 (35.1)
8.1–20.5 305 (33.9) 97 (34.5) 114 (37.3) 94 (30.0)
> 20.5 294 (32.7) 86 (30.6) 99 (32.4) 109 (34.8)
Data presented as N (%)
FACT/GOG-Ntx Functional Assessment of Cancer Treatment Gynecologic Oncology Group—Neurotoxicity
aServing size based on United States Department of Agriculture portion sizes
bPercent increase in neuropathy severity (based on self-reported score)
cChi-square (α = 0.05)
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Table 4 Self-reported change in neurotoxicity scores by tertiles of monthly servingsa of meats and other foods during treatment
(FACT/GOG-Ntx subscale) (n = 900)
Food group Total < 10%a 10–30%b > 30%b p valuec
Protein
Fish 0.98
≤ 1.5 320 (35.6) 101 (35.9) 110 (36.0) 109 (34.8)
1.6–5.0 287 (31.9) 91 (32.4) 98 (32.0) 98 (31.3)
> 5.0 293 (32.6) 89 (31.7) 98 (32.0) 106 (33.9)
Poultry 0.90
≤ 2.0 306 (34.0) 93 (33.1) 104 (34.0) 109 (34.8)
2.1–4.0 296 (32.9) 89 (31.7) 105 (34.3) 102 (32.6)
> 4.0 298 (33.1) 99 (35.2) 97 (31.7) 102 (32.6)
Red meats 0.98
≤ 5.0 319 (35.4) 97 (34.5) 111 (36.3) 111 (35.5)
5.1–12.0 281 (31.2) 91 (32.3) 92 (30.1) 98 (31.3)
> 12.0 300 (33.3) 93 (33.1) 103 (33.7) 104 (33.2)
Processed meat 0.87
≤ 3.3 306 (34.0) 95 (33.8) 102 (33.3) 109 (34.8)
3.4–8.8 294 (32.7) 89 (31.7) 107 (35.0) 98 (31.3)
> 8.8 300 (33.3) 97 (34.5) 97 (31.7) 106 (33.9)
Other proteins 0.47
≤ 6.0 311 (34.6) 97 (34.5) 98 (32.0) 116 (37.1)
6.1–15.3 296 (32.9) 85 (30.3) 107 (35.0) 104 (33.3)
> 15.3 293 (32.6) 99 (35.2) 101 (33.0) 93 (29.7)
Other foods
Dairy 0.31
≤ 16.3 300 (33.3) 89 (31.7) 99 (32.4) 112 (35.8)
16.3–39.5 300 (33.3) 87 (31.0) 113 (36.9) 100 (32.0)
> 39.5 300 (33.3) 105 (37.4) 94 (30.7) 101 (32.3)
Grains 0.01
≤ 27.5 301 (33.4) 78 (27.8) 97 (31.7) 126 (40.3)
27.6–48.5 299 (33.2) 93 (33.1) 109 (35.6) 97 (31.0)
> 48.5 300 (33.3) 110 (39.2) 100 (32.7) 90 (28.8)
Sweets 0.31
≤ 15.5 305 (33.9) 96 (34.2) 93 (30.4) 116 (37.1)
15.6–35.0 296 (32.9) 98 (34.9) 99 (32.4) 99 (31.6)
> 35.0 299 (33.2) 87 (30.96) 114 (37.3) 98 (31.3)
Fried foods 0.47
≤ 2.0 309 (34.3) 86 (30.6) 112 (36.6) 111 (35.5)
2.1–5.3 302 (33.6) 105 (37.4) 97 (31.7) 100 (32.0)
> 5.3 289 (32.1) 90 (32.0) 97 (31.7) 102 (32.6)
Added fats 0.41
≤ 17.3 303 (33.7) 89 (31.7) 98 (32.0) 116 (37.1)
17.3–34.0 299 (33.2) 103 (36.7) 101 (33.0) 95 (30.4)
> 34.0 298 (33.1) 89 (31.7) 107 (35.0) 102 (32.6)
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citrus fruits (OR = 1.08, 95% CI 0.93–1.25) and alco-
hol (OR = 0.94, 95% CI 0.80–1.09) were not signifi-
cant. The final adjusted model included age at
baseline, race/ethnicity, BMI at baseline, smoking sta-
tus, and menopausal status as well as all food groups.
In this model, the odds of reporting worse neur-
opathy decreased by 21% for each increase in tertile
of grain consumption (OR = 0.79, 95% CI 0.66–0.94,
p = 0.009) (Fig. 1). We also observed a 19% increase
with increasing consumption of citrus fruits (OR =
1.19, 95% CI 1.01–1.40, p = 0.05) in the final adjusted
model, although the risk estimate was not statistically
significant.
The majority of women reported increasing severity
of sensory neuropathy, which contributes most heavily
to the overall CIPN score. When analyses were lim-
ited to the sensory component of the CIPN score, we
observed associations similar to those seen with the
overall score for all food groups with the exception of
sweets. Odds of reporting worse sensory neuropathy
increased with each additional tertile of sweet con-
sumption (OR = 1.27, 95% CI 0.90–1.79; OR = 1.44,
95% CI 0.99–2.09, tertile 2 and 3, respectively) (data
not shown).
Discussion
In this study of diet during chemotherapy treatment in
women with breast cancer, we observed that consump-
tion of certain foods was associated with greater devel-
opment of CIPN symptoms. In our study population, we
observed that reporting worse neuropathy was associ-
ated with increasing age, being overweight or obese, a
change in weight from baseline, and being postmeno-
pausal. This is consistent with findings from a previous
Table 4 Self-reported change in neurotoxicity scores by tertiles of monthly servingsa of meats and other foods during treatment
(FACT/GOG-Ntx subscale) (n = 900) (Continued)
Food group Total < 10%a 10–30%b > 30%b p valuec
Alcohol 0.009
0.0 531 (59.0) 163 (58.0) 170 (55.6) 198 (63.3)
0.1–2.0 191 (21.2) 58 (20.6) 84 (27.5) 49 (15.7)
> 2.0 178 (19.8) 60 (21.4) 52 (17.0) 66 (21.1)
Data presented as N (%)
FACT/GOG-Ntx Functional Assessment of Cancer Treatment Gynecologic Oncology Group—Neurotoxicity
aServing size based on United States Department of Agriculture portion sizes
bPercent increase in neuropathy severity (based on self-reported score)
cChi-square (α = 0.05)
Fig. 1 Odds of increased self-reported FACT/GOG-Ntx scores and 95% CI by food groups consumed during treatment (n = 900). OR and 95% CI
estimated with ordinal logistic regression adjusted for age at baseline, race/ethnicity, BMI at baseline, smoking status, and menopausal status. CI
confidence interval, FACT/GOG-Ntx, Functional Assessment of Cancer Treatment Gynecologic Oncology Group—Neurotoxicity, LCL lower
confidence limit, OR odds ratio, UCL upper confidence limit
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analysis on dietary supplement use and CIPN in the lar-
ger cohort of breast cancer patients enrolled in S0221
[11]. After adjusting for age, race/ethnicity, BMI, smok-
ing status, highest achieved education, and food groups,
we observed significant inverse associations between
neuropathy and consumption of grains, and marginally
significant positive associations with consumption of cit-
rus fruits. We also observed a marginally significant
positive association between sensory neuropathy and
consumption of sweets.
Few studies have evaluated diet during chemotherapy
in relation to neurotoxicity. In a large prospective cohort
of breast cancer patients enrolled through Kaiser Perma-
nente Northern California with comprehensive measure-
ments of lifestyle factors, no association between fruit/
vegetable intake and clinically worse CIPN was observed
[10]. Contrary to this, we did observe a positive associ-
ation between consumption of citrus fruits and neur-
opathy symptoms. Due to the cross-sectional design of
the study, this observed positive association may be due
to the increased consumption of anti-inflammatory
foods with high flavones, flavanones, and vitamin C
among those attempting to manage their neuropathy. A
common myth is that citrus may promote inflammation,
although this is mostly triggered by the high fructose
content of some citrus fruits [25]. Eating foods that trig-
ger inflammation could increase pain symptoms associ-
ated with neuropathy by accelerating the inflammatory
process [26]. These foods can vary from person to per-
son, but most commonly include fried foods,
sugar-sweetened beverages, red and processed meat,
margarine, and refined grains [26]. Due to the design of
the FFQ used in this study, we were not able to separate
out the potential effects of refined grains alone. However,
when we restricted our analyses to sensory neuropathy,
we observed a marginally significant positive association
with sweets—foods that are high in refined carbohy-
drates—which may have contributed to an overall inflam-
matory effect and increased sensory symptomology.
The mechanism by which grain consumption may be
associated with decreased neuropathy severity observed
in our analysis is unclear. Refined grains tend to have
high glycemic load and are associated with increased risk
of diabetes and complications, including peripheral
neuropathy [27]. Consumption of whole grains, however,
is associated with lower risk of diabetes and associated
complications due to their antioxidant properties and
high levels of fiber [28, 29]. In our study, both refined
and whole grains were included in the grain food group,
as well as fortified grain products. Although the main
dietary sources of vitamin B12 are primarily meat prod-
ucts, fortified grain products can provide a significant
amount of vitamin B12 and folic acid [30]. Several vita-
min deficiencies, including vitamin E and vitamin B12,
have been associated with clinical symptoms similar to
that of peripheral neuropathy [31, 32]. Vitamin B12 sta-
tus has been linked to several neurological disorders, in-
cluding neuropathy and myelopathy, as well as several
brain disorders [33]. Folic acid is another B vitamin as-
sociated with neuron growth whose deficiency may in-
crease risk for peripheral neuropathy [34]. In a
secondary analysis, we found a significant association be-
tween tertile of cold cereal consumption and change in
neuropathy symptoms (chi-square p = 0.01; data not
shown). Those who consumed the highest tertile of cold
cereal were less likely to experience an increase in symp-
toms (n = 109, 38.8%). Dietary antioxidants linked to
phytochemicals found in the bran and germ fractions of
whole grain cereals may help to reduce oxidative
stress-mediated neuronal damage, although further re-
search is needed in this area [35, 36].
We compared population characteristics among those
included in the analysis and those who did not provide
information at baseline regarding neurotoxicity scores
and FFQ responses. Those who did not complete the
baseline neuropathy assessment were an average of 1.4
years younger. No other significant differences were ob-
served. Those who did not complete baseline FFQs were
slightly younger and premenopausal, more obese at
baseline, and less likely to be non-Hispanic White, have
completed high school, and be married or living as mar-
ried. Since many of these variables did not modify the
association between self-reported diet and neuropathy, it
is unlikely that failure to participate created a bias in our
results. As with most studies using dietary exposure, the
use of self-reported measures may be susceptible to re-
call bias. Due to the timing of the survey and the
cross-sectional design for analysis, the direction of the
association is unclear. Diet may have affected CIPN
symptoms or CIPN severity may have altered diet. Nau-
sea, vomiting, and loss of appetite are common side ef-
fects of chemotherapy that can lead to dramatic changes
in diet and weight gain [37]. In this study population, a
greater proportion of individuals who reported losing
weight during treatment was observed among those with
the greatest change in neuropathy scores (10.5%) com-
pared to those with moderate (4.9%) or no change
(2.9%). Treatment may increase sensitivity to certain
foods, resulting in a deviation from usual diet. This may
be true of alcohol consumption, for which the greatest
proportion of abstainers was observed among those ex-
periencing severe neuropathy. Further surveys should in-
clude an assessment of change in diet due to nausea,
dysgeusia, or change in appetite.
There are several, minor limitations in this study. We
acknowledge that all participants were part of a large
clinical trial and therefore results are not completely
generalizable. This was also an exploratory analysis that
Mongiovi et al. Breast Cancer Research          (2018) 20:146 Page 10 of 12
included multiple hypothesis tests within one model. Al-
though various components of diet were assessed, we
did not adjust for multiple comparisons as this analysis
was not based on preestablished hypotheses [38]. The
purpose of this cross-sectional analysis was to promote
additional hypothesis generation for more rigorous ana-
lyses. In our analyses, the inclusion of each dietary com-
ponent was also necessary to control for consumption of
that particular food group. We did not observe multicol-
linearity among food groups (0.35 ≤ r ≤ 0.52). Because in-
formation on both diet and neuropathy was collected at
the same time, there is a lack of temporality. Because al-
cohol was considered a food in our analyses, there may
have been reverse causality from inclusion of both
smoking and alcohol consumption. We also made as-
sumptions on missing values, assigning a value of 0 to
foods for which participants completed at least 50% of
the entire FFQ and a medium serving size when missing.
After reviewing the questionnaires, it appeared unlikely
that these foods were skipped but that nonresponse was
suggestive of lack of consumption.
Conclusions
While numerous studies on dietary supplements exist,
to our knowledge no other studies have examined the
associations between a comprehensive diet assessment
and CIPN among women with breast cancer. Our ana-
lysis was also novel in that we examined various food
groups as specific components of diet instead of an ag-
gregate total. We also distinguished between those who
experienced a moderate and severe change in neur-
opathy. By using this approach, we found that citrus fruit
and grain consumption may play a role in the neur-
opathy experience of some women undergoing chemo-
therapy. This is especially important since there are no
existing dietary recommendations for the management
of CIPN. Further research utilizing larger, prospective
studies is needed to investigate whether there may be
certain foods that could worsen or alleviate neuropathy
symptoms associated with treatment for breast cancer.
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